Insights Into Lung Cancer
Perspectives on management of patients with NSCLC and EGFR or ALK mutations, current use of treatment options including immunotherapy in advanced NSCLC, and treatment of progressive disease
Meeting Moderator
Sushil Bhardwaj, MD
Good Samaritan Hospital Suffern, NY, USA
Look Inside This Report
Download a sample of this report and start discovering the insights
Report Snapshot
Insights on the following therapies were obtained
- afatinib
- alectinib
- atezolizumab
- bevacizumab
- brigatinib
- carboplatin
- ceritinib
- crizotinib
- dacomitinib
- docetaxel
- erlotinib
- gefitinib
- gemcitabine
- lorlatinib
- nab-paclitaxel
- necitumumab
- nivolumab
- osimertinib
- pembrolizumab
- pemetrexed
- ramucirumab
GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT
- A moderated roundtable discussion focusing on treatment of NSCLC was held on August 24, 2019, in Washington, DC, USA
- Disease state and data presentations were developed in conjunction with a medical expert from Indiana University
- The group of advisors comprised 12 community oncologists
- Data collection was accomplished through use of audience response system questioning and in-depth moderated discussion
